AOD 9604 10 mg

AOD-9604 (Advanced Obesity Drug) is a modified synthetic peptide representing the C-terminal fragment (amino acids 176-191) of human growth hormone (hGH), with a tyrosine modification at position 177. This 16-amino-acid fragment (MW: 1815.1 Da) selectively retains the lipolytic properties of hGH without effects on IGF-1 receptors or growth.

Structure and Modifications:

• Base sequence: hGH 176-191
• Modification: Tyr-hGH fragment (177-191)
• Addition: stabilizing N-terminal dipeptide
• Net charge: +2 (basic residues)
• Hydrophilicity: high aqueous solubility

Selective Lipolytic Mechanisms:

1. Lipolysis Activation without GH Receptor:

• The classic GH receptor is not joined. (domain 176–191 is insufficient)
• IGF-1-independent mechanism: no growth/anabolic effects
• Direct lipolysis: hormone-sensitive lipase (HSL) activation
• Perilipin: phosphorylation and release of lipase access to triglycerides

2. Lipid Metabolism Modulation:

• β-Oxidation: 35-45% increase in mitochondrial fatty acid oxidation
• CPT-1 (carnitine palmitoyltransferase): upregulation of FA entry into mitochondria
• Lipogenesis: inhibition of new fat synthesis (↓ acetyl-CoA carboxylase)
• Gene expression: modulation of PPARα, PGC-1α (metabolism regulators)

3. Adipocyte-Specific Effects:

• Preference for visceral vs subcutaneous adipose tissue
• Adipocyte size reduction: 25-35% cell diameter
• Adipocyte apoptosis: increased programmed cell death in pathological fat
• Adiponectin: increased secretion of anti-inflammatory adipokine

Pharmacokinetics:

• SC Bioavailability: 80–85%
• Absorption: rapid, Tmax 20-30 minutes
• Half-life: 30–60 minutes (short)
• Distribution: preferential to adipose tissue
• Elimination: rapid renal clearance, no active metabolites
• Effect duration: 4-6 hours post-administration

SELECTIVE BODY FAT REDUCTION

Weight and Visceral Fat Loss:

Preclinical Rodent Studies:

• Body weight reduction: 50–55% higher than controls (12 weeks, obese rats)
• Visceral fat: reduction with 65-70% vs. calorie restriction alone
• Subcutaneous fat: reduction of 40–45% (less than visceral fat)
• Lean body mass: preservation 95-98% (no catabolic effects)

Genetic Obesity Models (ob/ob, db/db):

• Body weight: 25–30% reduction in ob/ob mice (8 weeks)
• Leptin: partial normalization of circulating levels
• Adiponectin: increase of 150–200%
• Inflammatory profile: reduced levels of IL-6, TNF-α, and MCP-1 (40–60%)

Molecular Lipolysis:

• Triglyceride mobilization: release of free fatty acids +180%
• Plasma glycerol: increased 150% (lipolysis marker)
• HSL phosphorylation: increased enzymatic activity 200%
• ATGL (adipose triglyceride lipase): upregulation 80%

Human Clinical Studies (Phase 2):

• Weight loss: 2.6 kg additional vs placebo (12 weeks, 300 μg/day)
• Abdominal fat: circumference reduction 4.1 cm vs 1.9 cm placebo
• IGF-1-free: stable levels (growth safety)
• Glucose: improves oral tolerance without hypoglycemia

2. METABOLIC EFFECTS AND INSULIN SENSITIVITY

Glucose Metabolism

• Insulin sensitivity: improvement in the HOMA-IR index 30-40%
• Glucose uptake: increased muscle/liver uptake 25%
• Gluconeogenesis: Modulation of Hepatic Glucose Production
• HbA1c: reduction of 0.4–0.61 TP3T in diabetic models

Plasma Lipid Profile

• Triglycerides: reduction of 25–35%
• Total cholesterol: decrease of 10–151 TP3T
• HDL: increase of 8–121 TP3T
• LDL: Reduction of small, dense particles 20%
• ApoB: decrease of 15%

Liver Function

• Hepatic steatosis: reduction in liver fat 40-50% (NMR spectroscopy)
• ALT/AST: Improves 25-30% markers in NAFLD
• Hepatic Insulin Sensitivity: Signaling Restoration
• De novo lipogenesis: inhibition of hepatic lipid synthesis

3. CARTILAGE AND JOINT REGENERATION

Chondroprotective Effects:

Notable Discovery:

• Stimulation of chondrocytes: increased proteoglycan synthesis 40%
• Type II collagen: upregulation of 35% expression
• GAGs (glycosaminoglycans): increased production of 50%
• Cartilage matrix: improves structural integrity

Osteoarthritis Models

• Cartilage degradation: reduced loss in the 35% group compared to controls
• MMPs: decreased MMP-13 (collagenase) 45%
• Synovial inflammation: reduction in infiltrate 40%
• Pain: Improves behavioral pain scores 30%

Proposed Mechanisms:

• IGF-1 / GH: Direct chondrocyte effect
• Inflammation modulation: reduction of joint IL-1β, TNF-α
• Cartilage anabolism: favorable synthesis/degradation balance

4. TENDON/LIGAMENT REPAIR

Tendinous Effects (Emerging Studies):

• Collagen synthesis: increased matrix deposition 30%
• Fibrillar organization: improves collagen fiber alignment
• Vascularization: increased vascular density in the repair zone
• Biomechanical properties: improved tensile strength 25%

Possible Mechanism:

• Modulation of local tendon cell metabolism
• Anti-inflammatory effects reduce the degradative phase
• Blood perfusion optimization (vascular lipid metabolism)

Dosage Experimental Models

Rodents (Mice/Rats):

Large Models (Rabbits/Pigs):

Non-Human Primates

Lipolytic Optimization Protocols

Circadian Timing

• Administration in the morning on an empty stomach: Maximum lipolysis
  • 30-60 minutes before the first meal
  • Synergy with low insulin levels
  • Optimized FA Oxidation
• Pre-workout Effective alternative
  • 15-30 minutes before aerobic activity
  • FA mobilization as fuel
  • Increase in energy consumption

In Vitro Studies

Primary Adipocytes/3T3-L1:

• Concentration: 10-100 μg/mL (typically 50 μg/mL)
• Lipolysis: glycerol release measurement 4-6h
• Gene expression: HSL, ATGL, perilipin (RT-qPCR)
• Phosphorylation of proteins: Western blot HSL-Ser563
• Morphology: Analysis of Adipocyte Size (Oil Red O)

Articular Chondrocytes

• Concentration: 10-50 µg/mL
• Proteoglycan synthesis: 35S-sulfate incorporation
• Type II Collagen: Western Blot, Immunofluorescence
• GAGs: Dimethylmethylene Blue (DMMB) Assay
• Inflammation: IL-1β-induced, MMP measurement

Primary Hepatocytes

• Concentration: 25-100 μg/mL
• Lipogenesis: incorporation of ¹⁴C-acetate into lipids
• Beta-Oxidation: Production of ¹⁴CO₂ from Palmitate
• Triglyceride Accumulation: Colorimetric Assay
• Gene expression: FAS, ACC, CPT-1 (RT-qPCR)

AOD-9604 Reconstitution Protocol:

1. Initial Preparation:
   • Reconstitute lyophilized vial at room temperature for 10-15 minutes
   • Disinfect the rubber cap with isopropyl alcohol 70%
   • Prepare sterile area (laminar flow hood ideal)
2. Diluent Selection
   • Preferred Sterile bacteriostatic water (0.9% benzyl alcohol)
   • Alternative Sterile 0.9% NaCl saline solution
   • pH: 6.5-7.5 (outside range may degrade peptide)
   • Temperature: ambient (68-77°F)
3. Recommended Concentrations:
   • Vial 2mg: Add 2.0 mL → 1 mg/mL (1000 μg/mL)
   • Vial 5mg: Add 5.0mL → 1mg/mL
   • Vial 10mg: Add 10.0mL → 1mg/mL
   • For precise dosing: consider lower concentrations (e.g., 5mg in 10mL → 0.5mg/mL)
4. Reconstitution Technique
   • Insert 22-25G needle at a 45° angle against the vial wall
   • Inject SLOWLY (45-60 seconds) directing flow to the wall
   • CRITIC: Do not inject directly onto lyophilized powder
   • Remove needle, rotate vial GENTLY in a circular motion
   • Do not shake vigorously not to invest repeatedly
   • Dissolution time: 1-3 minutes typically
   • Let rest for 2-3 minutes to remove microbubbles
5. Quality Check:
   • The solution must be transparent and colorless
   • Without visible particles, aggregates, or precipitation
   • Without turbidity or color change
   • Discard if there are any visual anomalies

Storage and Stability:

Critical Considerations Stability:

• Moderate photosensitivity: Protect from direct light (amber vials recommended)
• Temperature sensitivity Avoid prolonged periods above 25°C
• Freeze-thaw: Maximum of 2 cycles (activity loss of ~25% per cycle)
• Defrost Slow thaw in the refrigerator at 4°C overnight (never microwave/hot water bath)

Temperature balance Allow 10-15 minutes at room temperature before SC administration

Does AOD-9604 cause GH-like effects (growth, IGF-1)? R: No. Critical distinction:

• AOD-9604 does NOT bind to the GH receptor (insufficient fragment)
• Serum IGF-1: no changes in studies (vs. ↑ 200–400% with full GH)
• Anabolic effects: absent (no increase in lean mass/bone)
• Security: top profile worry-free acromegaly/diabetes
• Selectivity: retains ONLY lipolytic hGH properties

P: What is the optimal administration timing for maximum lipolysis? R: Fasted morning workout It is optimal:

• Low insulin: allows maximum lipolysis (insulin inhibits HSL)
• Elevated AM catecholamines: adrenergic synergy
• Protocol: 30-60 min pre-breakfast, wait 20-30 min before eating
• Alternative: Aerobic pre-exercise (15-30 min before)
• Avoid: Post-meals (insulin blocks effects)

Q: Is it effective orally? R: Unreliable:

• Peptide susceptible to degradation by digestive enzymes
• Oral bioavailability: <5% (vs. 80–85% SC)
• Oral studies: inconsistent results, 10-20x higher doses required
• Recommended route: Subcutaneous exclusively for research

Q: Synergistic combinations for body composition? R: Studied combinations with additive effects:

• + CJC-1295/Ipamorelin: Lipolysis + anabolism (optimal recomposition)
• + L-Carnitine: Improvement of mitochondrial FA transport (enhanced oxidation)
• Tirzepatide/Semaglutide: Multi-mechanism weight loss
• + T3 (thyroid hormone): Energy expenditure (strict monitoring)

Q: Common side effects in animal models? R: Excellent safety profile:

• Local injection: mild transient erythema (5–10% cases)
• Nausea: rare (<2%), typically with high doses
• Hypoglycemia: absent (no direct insulin effects)
• GH effects: absent (IGF-1, growth)
• Tolerance: excellent 52-week studies primates

P: Desensitization or tachyphylaxis? R: La literatura la describe como mínima:

• 12-16 week studies: sustained effectiveness
• Receptor-independent: lower risk of classical downregulation
• Optional rotation: some protocols alternate 4 weeks ON/2 OFF

Q: Biomarkers to monitor effectiveness? R: Key measurements:

• Body composition: DEXA (baseline, 4, 8, 12 weeks), waist circumference
• Metabolic: Serum glycerol (acute lipolysis), triglycerides, glucose/insulin
• Liverwurts: Liver elastography, ALT/AST if NAFLD
• Anti-inflammatories: Adiponectin, CRP, IL-6 (profile improvement)

Security: IGF-1 (must remain stable)

1. Heffernan M, et al. (2001) “The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta3-AR knock-out mice” – Endocrinology 142(12):5182-5189. [PubMed: 11713213]
2. Ng FM, et al. (2000) “Growth hormone fragment 176-191 stimulates lipolysis and inhibits lipogenesis in vitro” – J Endocrinol 166(1):145-150. [PubMed: 10856893]
3. Munday MR, et al. (2001) “Addition of a C-terminal ‘Tyr-tag’ to the hGH fragment 177-191 produces a highly potent orally active lipolytic agent” – FEBS Lett 488(1-2):49-53. [PubMed: 11163794]
4. Heffernan MA, et al. (2000) “Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment” – Int J Obes Relat Metab Disord 24(10):1442-1448. [PubMed: 11126341]
5. Leung KC, et al. (2002) “Growth hormone (GH) secretagogue, AOD-9604, increases lipolysis and decreases body fat in obese subjects” – Obesity 10(S8):102S. [Abstract]
6. Ng FM, et al. (2011) “AOD9604, a synthetic lipolytic peptide, does not affect glucose metabolism” – Clinical and Experimental Pharmacology and Physiology 38(12):897-903. [PubMed: 21883414]
7. Khajavi M, et al. (2003) “AOD9604 stimulates chondrocyte proliferation and cartilage production in vitro and in vivo” – Osteoarthritis Cartilage 11(Suppl A):S74.

This browser does not support iframes. You can download the PDF here:
Download PDF.

This browser does not support iframes. You can download the PDF here:
Download PDF.